Suchergebnisse - "Antibodies, Monoclonal, Humanized"

PubPharm (19)

1

Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189) : a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

enthalten in: The lancet / Oncology | March 2020

von Garassino, M. | Gadgeel, S. | Esteban, E. | +16

2

Clinical review report : Alexion Pharma Canada corporation : indication : adult patients with generalized myasthenia gravisEculizumab (Soliris)

Erschienen: Ottawa (ON), Canadian Agency for Drugs and Technologies in Health, December 2020

CADTH common drug review

Version: Final (with redactions).

3

Clinical review report : indication : for the treatment of adult patients with active ankylosing spondylitis who have responded inadequately to, or are intolerant to conventional therapyIxekizumab (Taltz) (Eli Lilly Canada Inc.)

Erschienen: Ottawa (ON), Canadian Agency for Drugs and Technologies in Health, May 2020

CADTH common drug review

Version: Final (with redactions).

4

Pharmacoeconomic review report : indication: indicated in addition to standard therapy for reducing disease activity in adult patients with active, autoantibody-positive systemic lupus erythematosusBelimumab (Benlysta) (GlaxoSmithKline Inc.)

Erschienen: Ottawa (ON), CADTH, June 2020

CADTH common drug review

Final (with redactions).

5

HER2-targeted therapy influences CTC status in metastatic breast cancer

enthalten in: Breast cancer research and treatment | 2020 May 20

von Deutsch, T. | Riethdorf, S. | Fremd, C. | +9

6

Proportion of Severe Asthma Patients Eligible for Mepolizumab Therapy by Age and Age of Onset of Asthma

enthalten in: The journal of allergy and clinical immunology. In practice | 2019

von Comberiati, P. | McCormack, K. | Malka-Rais, J. | +1

CommentIn: J Allergy Clin Immunol Pract. 2019 Nov - Dec;7(8):2697-2698. - PMID 31706492

7

Immune checkpoint inhibitors for classical Hodgkin lymphoma in brentuximab vedotin-naïve patients : a review of clinical effectiveness, cost-effectiveness, and guidelines

Erschienen: Ottawa (ON), CADTH, June 21, 2019

CADTH rapid response report: summary with critical appraisal

Version 1.0.

von Williams, D. | Gray, C. | Picheca, L.

8

Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study : evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer

enthalten in: European journal of cancer | January 2018

von Schneeweiss, A. | Chia, S. | Hickish, T. | +6

9

How should we treat older adults with Ph+ adult ALL and what novel approaches are being investigated?

enthalten in: Best practice & research. Clinical haematology | 2017

von Wieduwilt, M.

10

Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation

enthalten in: Clinical journal of the American Society of Nephrology : CJASN | 2017

von Fakhouri, F. | Fila, M. | Provôt, F. | +14